Summary
Two prerequisites in a successful search for cardiac glycosides are the separability of the inotropicallyactive from the toxically-active component and knowledge of their structure-activity relationships and/or indispensible structural features. A number of papers show that toxic effects of heart glycosides are dependent upon inhibition of the Na+, K+-transport ATPase. This is not, however, the case with the inotropic effect, which has been shown not to be causally related to inhibition of the ATPase. Thus it is reasonable to assume that the search for selectively active compounds with the digitalis effect will be met with success. At present, however, there are no assumptions which can be made about the dependence of the pharmacological effect upon the structure. This would of course allow the prediction of structural details of the effective inotropic substance, and thus make possible its synthesis. Various studies have disproved the dogmas which have been adhered to for a long time. The structure-activity relationships are still obscure, although a host of individual phenomena are known. Some insight, however, results from those cases in which either the animal therapeutic index of this class of compounds is increased, or the frequency of arrhythmias is diminished. In elucidating such properies, the array of test methods used is of great importance. Methods, frequently applied today, such as the one determining the toxicity in the cat (Hatcher) or the ATPase test can easily lead to wrong conclusions unless they are used in conjunction with more revealing tests for inotropy.
Similar content being viewed by others
References
W. Diederen and R. Kadatz, Ärztl. Forsch.24, 149 (1974)
M. A. Kimble and R. M. Elenbaas, J. Am. pharm. Ass.14, 362 (1974).
Cardiac Glycoside Therapy, in: Evaluations of Drug Interactions, p. 295. American Pharmaceutical Association, Washington, 1973. 1st ed.
G. K. Moe and A. E. Farah, in: The Pharmacological Basis of Therapeutics, 5th ed., p. 653, Ed. L. S. Goodman and A. Gilman, Macmillan Publ. Co. Inc, New York 1975.
K. Repke, Internist7, 418 (1966).
K. S. Lee and W. Klaus, Pharmac. Rev.23, 193 (1971).
T. Godfraind, Biochem. Pharmac.24, 823 (1975).
K. R. H. Repke, R. Schön, W. Henke, W. Schönfeld, B. Streckenbach and F. Dittrich, Ann. N. Y. Acad. Sci.242, 203 (1974).
R. E. Ten Eick, A. L. Bassett and G. T. Okita, J. Pharmac. exp. Ther.185, 12 (1973).
G. T. Okita, F. Richardson and B. F. Roth-Schechter, J. Pharmac. exp. Ther.185, 1 (1973).
G. T. Okita, Proc. West Pharmac. Soc.18, 14 (1975).
R. Mendez, G. Pastelin and E. Kabela, J. Pharmac. Exp. Ther.188, 189 (1974).
H. Lüllmann and T. Peters, Adv. Cardiol.12, 174 (1974).
T. Peters, R.-H. Raben and O. Wassermann, Eur. J. Pharmac.26, 166 (1974).
B. G. Katzung, J. A. Munoz, D. Y. Shirachi, A. J. Trevor, H. H. Chang and M. E. Wolff, Experientia26, 1189 (1970).
T. Akera, S. I. Baskin, T. Tobin and T. M. Brody, Recent Adv. Stud. Card. Struct. Metab.4, 149 (1974).
C. Hegevary, Mol. Pharmac.11, 588 (1975).
R. Thomas, J. Boutagy and A. Gelbart, J. pharma. Sci.63, 1649 (1974).
R. V. Murthy, A. M. Kidwai and E. E. Daniel, J. Pharmac. exp. Ther.188, 575 (1974).
D. Ku, T. Akera, C. L. Pew and T. M. Brody, Naunyn-Schmiedebergs Arch. Pharmac.285, 185 (1974).
H. Lüllmann, T. Peters and K.-U. Seiler, Dt. med. Wschr.96, 1018 (1971).
H. Lüllmann and T. Peters, Eur. J. Pharmac.14, 204 (1971).
W. G. Sanborn and G. A. Langer, J. gen. Physiol.56, 191 (1970).
G. A. Langer and J. S. Frank, J. Cell Biol.54, 441 (1972).
W. G. Nayler, J. molec. Cell Cardiol.5, 101 (1973).
A. E. Ruoho, L. E. Hokin, R. J. Hemingway and S. M. Kupchan, Science159, 1354 (1968).
M. E. Wolff and W. Ho, J. pharm. Sci.56, 705 (1967).
A. H. El Masry, S. A. El Defrawy and O. Gisvold, J. pharm. Sci.58, 228 (1969).
M. E. Wolff, W. Ho and H.-H. Chang, J. med. Chem.13, 657 (1970).
J. E. Doherty and J. J. Kane, Drugs6, 182 (1973).
Ch. Tamm, in: Proc. 1st International Pharmac. Meeting, Stockholm, vol. 3, p. 11. Ed. W. Wilbrand. Pergamon Press, Oxford 1963.
T. Shigei, H. Tsuru, Y. Saito and M. Okada, Experientia29, 449 (1973).
G. Kuschinsky and H. Lüllmann, in: Kurzes Lehrbuch der Pharmakologie, 4, Aufl., p. 51, Thieme, Stuttgart 1970.
G. Kroneberg, K. H. Meyer, E. Schraufstätter, S. Schütz and K. Stoepel, Naturwissenschaften51, 192 (1964).
K. R. H. Repke, Pharmazie27, 693 (1972).
R. J. Luchi and H. L. Conn, Prog. cardiovasc. Dis.7, 336 (1965).
W. Saito, Y. Kanemasa and M. Okada, Chem. Pharm. Bull.18, 629 (1970).
W. Zürcher, E. Weiss-Berg and Ch. Tamm, Helv. chim. Acta52, 2449 (1969).
T. R. Witty, W. A. Remers and H. R. Besch, J. pharm. Sci.64, 1248 (1975).
K. Meyer, Planta med., suppl. 4, 1971.
N. Ishikawa, H. Tsurn, T. Shigei, T. Anjyo and M. Okada, Experientia30, 1308 (1974).
P. G. Marshall, in: Rodd's Chemistry of Carbon Compounds, 2nd ed., vol. II, part D, p. 360, Ed. S.Coffrey. Elsevier Publ. Co., Amsterdam, London, New York 1970.
J. G. Baumgarten, in: Die herzwirksamen Glykoside, p. 212. Thieme Verlag, Leipzig 1963.
M. Okada and Y. Saito, Chem. Pharm. Bull.16, 2223 (1968).
T. Shigei and S.Mineshita, Experientia24, 466 (1968).
M. S. Ragab, H. H. A. Linde and K. Meyer, Helv. chim. Acta45, 1794 (1962).
R. Deghenghi, in: Chemistry of Natural Products. 6. Internat. Symp. Mexico City 1969, p. 153. Butterworths, London 1970.
J. Boutagy, A. Gelbart and R. Thomas, Aust. J. pharm. Sci.2, 41 (1973).
W. Eberlein, J. Heider and H. Machleidt, Chem. Ber.107, 1275 (1974).
H.-J. Portius and K. Repke, Arzneimittel-Forsch.14, 1073 (1964).
W. Eberlein, J. Nickl, J. Heider, G. Dahms and H. Machleidt, Chem. Ber.105 3686 (1972).
K. Meyer, Helv. chim. Acta35, 2444 (1952).
U. Stache, K. Radscheit, W. Fritsch and W. Haede, Liebigs Ann. Chem.1974, 608.
T. Shigei, M. Katori, H. Murase and S. Imai, Experientia20, 572 (1964).
M. Okada and Y. Saito, Chem. Pharm. Bull.15, 352 (1967).
F. G. Henderson and K. K. Chen, J. med. Chem.8, 577 (1965).
B. K. Naidoo, T. R. Witty, W. A. Remers and H. R. Besch, J. pharm. Sci.63, 1391 (1974).
A. Kovařiková, H. Kolárová and J. Pitra, Experientia20, 263 (1964).
K.-O. Haustein, F. Markwardt and K. R. H. Repke, Eur. J. Pharmac.10, 1 (1970).
K.-O. Haustein and J. Hauptmann, Pharmacology11, 129 (1974).
M. Vasalle, J. Karis and B. F. Hoffman, Am. J. Physiol.203, 433 (1962).
L. Sawlewicz, E. Weiss, H. H. A. Linde and K. Meyer, Helv. chim. Acta55, 2452 (1972).
E. Hauser, U. Boffo, L. Meister, L. Sawlewicz, H. H. A. Linde and K. Meyer, Helv. chim. Acta56, 2782 (1973).
U. Stache, W. Haede, W. Fritsch, K. Radscheit and E. Lindner, DOS 2013032 (1971), CA 76, 14816 b (1972).
K. Meyer, DOS 2137047 (1972), CA 76, 141218, CA 84, 59879.
R. Mutschler, in: Arzneimittelwirkungen. 1. Aufl., p. 236. Wissenschaftl. Verlagsgesellschaft. Stuttgart 1970.
Author information
Authors and Affiliations
Additional information
Acknowledgment. The authors are very grateful to J. Berger and Dr M. Sayare for their kind help and advice in writing the English version of the manuscript, as well as for support by the Swiss National Science Foundation.
Rights and permissions
About this article
Cite this article
Güntert, T.W., Linde, H.H.A. Cardiac glycosides: Prerequisites for the development of new cardiotonic compounds. Experientia 33, 697–703 (1977). https://doi.org/10.1007/BF01944136
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01944136